文献速递糖尿病

人脂肪来源间充质干细胞预防免疫检查点阻断诱导的1型糖尿病

Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
PubMed 文献 · Diabetologia · 2022-05-05

研究在雄性NOD小鼠中观察人脂肪来源间充质干细胞(MSC)能否预防抗PD-L1单抗诱导的1型糖尿病。抗PD-L1单抗单独组25只中16只(64%)发生糖尿病,联合MSC组21只中4只(19%)发生。MSC减少胰岛T细胞和CXCL9阳性巨噬细胞浸润并改善胰岛素含量和β细胞面积。

要点

  • 抗PD-L1单抗使雄性NOD小鼠糖尿病发生率为64%(16/25),联合人脂肪来源MSC后降至19%(4/21)。
  • MSC显著减少胰岛CD3阳性T细胞(45%)和CXCL9阳性巨噬细胞(67%)聚集。
  • MSC改善胰岛素含量(1.9倍)和胰岛β细胞面积(2.7倍),并改变血浆外泌体水平和细胞因子谱。

核心结论

  • 结果提示MSC可预防免疫检查点癌症治疗相关的糖尿病发生,可能值得进一步考虑作为新的辅助细胞治疗。

研究设计与样本

  • 在雄性NOD小鼠中经尾静脉注射人脂肪来源MSC,并以 purified PD-L1 monoclonal antibody 诱导糖尿病。
  • 对NOD小鼠及一例ICI治疗后发生糖尿病的癌症患者胰腺切片中的T细胞、巨噬细胞及表达CXCL9的单核细胞来源巨噬细胞进行免疫荧光分析。
  • 同时研究注射MSC的组织定位、血浆外泌体水平和血浆细胞因子谱。

主要发现

  • 抗PD-L1单抗未联合hMSC组[MSC(-)]25只NOD小鼠中16只(64%)发生糖尿病,联合hMSC组[MSC(+)]21只中4只(19%)发生。
  • PD-1/PD-L1阻断使胰岛CD3阳性T细胞面积增加6.2倍、Mac-2抗原阳性巨噬细胞增加2.5倍、CXCL9阳性巨噬细胞增加40.3倍。
  • MSC使胰岛T细胞聚集减少45%、CXCL9阳性巨噬细胞聚集减少67%,并使胰岛素含量改善1.9倍、胰岛β细胞面积改善2.7倍。
  • PD-1/PD-L1阻断后T细胞和CXCL9阳性巨噬细胞浸润至胰岛β细胞间的缝隙,MSC largely prevented such immune cell infiltration。
  • CXCL9阳性巨噬细胞在ICI治疗后发生糖尿病的癌症患者胰岛中可见,而在对照患者胰岛中少见。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Immunomodulators blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) have improved the treatment of a broad spectrum of cancers. These immune checkpoint inhibitors (ICIs) reactivate the immune system against tumour cells but can also trigger autoimmune side effects, including type 1 diabetes. Mesenchymal stem cell (MSC) therapy is the most prevalent cell therapy, with tissue-regenerating, anti-fibrosis and immunomodulatory functions provided by the secretome of the cells. Here, we examined whether systemic MSC treatment could prevent the development of type 1 diabetes in a NOD mouse model. METHODS: The purified PD-L1 monoclonal antibody was administered to induce diabetes in male NOD mice which normally do not develop diabetes. Human adipose-derived MSCs were administered by tail vein injections. T cells, macrophages and monocyte-derived macrophages expressing C-X-C motif chemokine ligand 9 (CXCL9) in pancreatic sections of NOD mice and a cancer patient who developed diabetes following the ICI treatments were analysed by immunofluorescence. Tissue localisation of the injected MSCs, plasma exosome levels and plasma cytokine profiles were also investigated. RESULTS: PD-1/PD-L1 blockade induced diabetes in 16 of 25 (64%) NOD mice which received anti-PD-L1 mAb without hMSCs [MSC(-)], whereas MSC administration decreased the incidence to four of 21 (19%) NOD mice which received anti-PD-L1 mAb and hMSCs [MSC(+)]. The PD-1/PD-L1 blockade significantly increased the area of CD3-positive T cells (6.2-fold) and macrophage-2 (Mac-2) antigen (2.5-fold)- and CXCL9 (40.3-fold)-positive macrophages in the islets. MSCs significantly reduced T cell (45%) and CXCL9-positive macrophage (67%) accumulation in the islets and the occurrence of diabetes. The insulin content (1.9-fold) and islet beta cell area (2.7-fold) were also improved by MSCs. T cells and CXCL9-positive macrophages infiltrated into the intricate gaps between the beta cells in the islets by PD-1/PD-L1 blockade. Such immune cell infiltration was largely prevented by MSCs. The most striking difference was observed in the CXCL9-positive macrophages, which normally did not reside in the beta cell region in the islets but abundantly accumulated in this area after PD-1/PD-L1 blockade and were prevented by MSCs. The CXCL9-positive macrophages were also observed in the islets of a cancer patient who developed diabetes following the administration of ICIs but few CXCL9-positive macrophages were observed in a control patient. Mechanistically, the injected MSCs accumulated in the lung but not in the pancreas and strongly increased plasma exosome levels and changed plasma cytokine profiles. CONCLUSIONS/INTERPRETATION: Our results suggest that MSCs can prevent the incidence of diabetes associated with immune checkpoint cancer therapy and may be worth further consideration for new adjuvant cell therapy.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Kawada-Horitani E, Kita S, Okita T, et al. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade. Diabetologia. 2022. PMID: 35511238. doi:10.1007/s00125-022-05708-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。